Highlights of This Issue 4417

SPECIAL FEATURES

CCR Translations

4419  TP53 Mutations and Lung Cancer: Not All Mutations Are Created Equal
       Ramaswamy Govindan and Jason Weber
       See related article, p. 4647

4422  “Companion Diagnostics”: Has Their Time Come and Gone?
       Fred R. Hirsch, Paul A. Bunn Jr, and Roy S. Herbst
       See related article, p. 4488

CCR New Strategies

4425  New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs
       Juliane M. Jurgensmeier, Joseph P. Eder, and Roy S. Herbst

CCR Perspectives in Drug Approval

4436  FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
       Laleh Amiri-Kordestani, Gideon M. Blumenthal, Qiang Casey Xu, Lijun Zhang, Shenghui W. Tang, Linan Ha, Wendy C. Weinberg, Bo Chi, Reyes Candau-Chacon, Patricia Hughes, Anne M. Russell, Sarah Pope Mikinski, Xiao Hong Chen, W. David McGuinn, Todd Palmby, Sarah Mackenzie, Ulrich D. Ellenhorn, Don J. Diamond, and Vincent Chung

4442  Molecular Pathways: Targeting ETS Gene Fusions in Cancer
       Felix Y. Feng, J. Chad Brenner, Maha Hussain, and Arul M. Chinnaiyan

4449  Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)

4459  p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses
       Nicola R. Hardwick, Mary Carroll, Teodora Kaltcheva, Dajun Qian, Dean Lim, Lucille Leong, Peiguo Chu, Joseph Kim, Joseph Chao, Marwan Fakih, Yun Yen, Jonathan Espenschied, Joshua D.L. Ellenhorn, Don J. Diamond, and Vincent Chung

4471  Phase I Safety and Pharmacodynamic of Inecalitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients
       Jacques Medioni, Gai Deplanque, Jean-Marc Ferrero, Tristan Maurina, Jean-Michel P. Rodier, Eric Raymond, Jorge Alivon, Gerard Maruani, Pascal Houiller, Sarah Mackenzie, Stephanie Renaux, Jean-Francois Dufour-Lamartine, Reza Elaïdi, Celine Lerest, and Stephane Oudard

PERSONALIZED MEDICINE AND IMAGING

4478  Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non–Small Cell Lung Cancer
       Christiane Amendt, Eike Staub, Manja Friese-Hamim, Jacques Medioni, Pascal Houiller, Sarah Mackenzie, Stephane Oudard, and Christopher Stroh

4488  Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
       See related commentary, p. 4422
Alet-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy

Zenia Saridaki, Joanne B. Weidhaas, Heinz-Josef Lenz, Pierre Laurent-Puig, Bart Jacobs, Jef De Schutter, Wendy De Roock, David W. Salzman, Wu Zhang, Dongyun Yang, Camilla Pilati, Olivier Bouché, Hubert Piessevaux, and Sabine Tejpar

FcγRIIa and FcγRIIIa Polymorphisms and Cetuximab Benefit in the Microscopic Disease

Francesco Sclafani, David Gonzalez de Castro, David Cunningham, Sanna Hulkki Wilson, Clare Peckitt, Jaume Capdevila, Bengt Glimelius, Susana Rosell, Andrew Wotherspoon, Gina Brown, Diana Tait, Ruwaida Begum, Janet Thomas, Jacqueline Oates, and Ian Chau

Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts


Noninvasive Detection of Glutamate Predicts Survival in Pediatric Medulloblastoma

Martin Wilson, Simonandip K. Gill, Lesley MacPherson, Martin English, Theodoros N. Arvanitis, and Andrew C. Peet

Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of IGH


The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer

Alison Backen, Andrew C. Renezhe, Andrew R. Clamp, Carlo Berzuini, Cong Zhou, Amit Oza, Selina Bannoo, Stefan J. Scherer, Rosamonde E. Banks, Caroline Dive, and Gordon C. Jayson

Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer

Zhe Zhang, Jiping Wang, Dongmei Ji, Chencheng Wang, Ruijiao Liu, Zheng Wu, Lian Liu, Dan Zhu, Jinjia Chang, Ruixuan Geng, Lei Xiong, Qiangyi Fang, and Jin Li

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

Jutta Deckert, Marie-Cécile Wetzel, Laura M. Bartle, Anna Skaletskaya, Victor S. Golshacher, François Vallée, Qing Zhou-Liu, Paul Ferraro, Stéphanie Pouzieux, Charlotte Lahoute, Charles Dumontet, Adriana Plesa, Marielle Chiron, Pascale Lejeune, Thomas Chittenden, Peter U. Park, and Véronique Blanc

Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth

Savita Sankar, Emily R. Theisen, Jared Bearss, Timothy Mulvihill, Laura M. Hoffman, Venkataszwamy Soma, Mary C. Beckerle, Sunil Sharma, and Stephen L. Lessnick

Large-Scale Characterization of DNA Methylation Changes in Human Gastric Carcinomas with and without Metastasis

Zhaojun Liu, Jun Zhang, Yanhong Gao, Lirong Pei, Jing Zhou, Liankun Gu, Lianhai Zhang, Budong Zhu, Naoko Hatton, Jiafui Ji, Yasuhito Yuasa, Wooho Kim, Toshikazu Ushijima, Huidong Shi, and Dajun Deng

Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002

Sébastien Couraud, Felipe Vaca-Paniagua, Stéphanie Villar, Javier Oliver, Tibor Schuster, Hélène Blanché, Nicolas Girard, Jean Trédaniel, Laurent Guillenminault, Radj Cervais, Nathalie Prim, Michel Vincent, Jacques Margery, Sébastien Larivère, Pascal Foucher, Bernard Duvert, Maxime Vallée, Florence Le Calvez-Klein, James McKay, Pascale Missy, Franck Morin, Gérard Zalcman, Magali Olivier, and Pierre-Jean Souquet for the BioCAST/IFCT-1002 investigators
ABOUT THE COVER

The cover shows the crystal structure of the SAR650984-Fab in complex with human CD38 resolved at 1.53 Å resolution. A close-up view of the epitope highlights the interface between human CD38 and SAR650984-Fab, which involves mainly antibody heavy chain CDR loop H3 (yellow) and light chain CDR loops L1, L2 and L3 (green). For details, see the article by Deckert and colleagues on page 4574 of this issue.

<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://clincancerres.aacrjournals.org/content/20/17">http://clincancerres.aacrjournals.org/content/20/17</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>E-mail alerts</td>
<td>Sign up to receive free email-alerts related to this article or journal.</td>
</tr>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, use this link <a href="http://clincancerres.aacrjournals.org/content/20/17">http://clincancerres.aacrjournals.org/content/20/17</a>. Click on &quot;Request Permissions&quot; which will take you to the Copyright Clearance Center's (CCC) Rightslink site.</td>
</tr>
</tbody>
</table>